Interleukin-23 inhibitors demonstrate high effectiveness in the treatment of a real-world cohort of 82 psoriatic patients regardless of the HLA-Cw6 status
Dermatol Ther
.
2022 Oct;35(10):e15741.
doi: 10.1111/dth.15741.
Epub 2022 Aug 9.
Authors
Carmen Alejandra Rubio-Muniz
1
,
Alba Lopez-Valle
1
,
Manuel Agud-Dios
1
,
Jorge Arroyo-Andres
1
,
Raquel Rivera-Díaz
1
Affiliation
1
Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain.
PMID:
35899602
DOI:
10.1111/dth.15741
No abstract available
Publication types
Letter
MeSH terms
Arthritis, Psoriatic*
HLA-C Antigens / genetics
Humans
Interleukin Inhibitors
Interleukin-23
Psoriasis* / drug therapy
Substances
HLA-C Antigens
HLA-C*06 antigen
Interleukin Inhibitors
Interleukin-23